Mymetics Corp (MYMX)

[Work Harder]

Following a May 2013 research alliance between the companies focused on respiratory allergy therapies, immunotherapy specialist Stallergenes has partnered with DBV Technologies to develop and commercialise a treatment for birch pollen allergy using DBV’s Viaskin® epicutaneous drug delivery technology, which modulates the immune response to allergens...

http://www.pharmadeals.net/journal/pharmadealsreview/details/1987

https://au.linkedin.com/in/eric-potier-a345ab192/en-us?challengeId=AQHonmKHNvCy_gAAAXMvKry4LvMwoMKMMdRtT8MjL_VTuS6tymf0udNwx75pzVMsrdy88uJU68cvtLfZKPhdfisBVjhJFOLB8A&submissionId=af0250cc-75d2-1f16-5b93-e0a5e07d086a